Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,358,304
  • Shares Outstanding, K 5,666,990
  • Annual Sales, $ 58,496 M
  • Annual Income, $ 2,119 M
  • EBIT $ 10,649 M
  • EBITDA $ 16,939 M
  • 60-Month Beta 0.67
  • Price/Sales 2.43
  • Price/Cash Flow 8.44
  • Price/Book 1.54

Options Overview Details

View History
  • Implied Volatility 25.69% ( -0.04%)
  • Historical Volatility 23.18%
  • IV Percentile 53%
  • IV Rank 51.79%
  • IV High 32.70% on 04/12/24
  • IV Low 18.16% on 05/13/24
  • Put/Call Vol Ratio 0.32
  • Today's Volume 423,848
  • Volume Avg (30-Day) 224,866
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 3,356,390
  • Open Int (30-Day) 3,108,139

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.49
  • Number of Estimates 7
  • High Estimate 0.65
  • Low Estimate 0.39
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +390.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.48 +4.78%
on 11/15/24
29.17 -12.07%
on 10/29/24
-3.19 (-11.06%)
since 10/22/24
3-Month
24.48 +4.78%
on 11/15/24
30.43 -15.71%
on 10/09/24
-3.13 (-10.88%)
since 08/22/24
52-Week
24.48 +4.78%
on 11/15/24
31.54 -18.67%
on 07/30/24
-4.67 (-15.40%)
since 11/22/23

Most Recent Stories

More News
3 Dividend Stocks That Are Screaming Buys in November

Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.

JNJ : 155.17 (-0.21%)
ABBV : 176.95 (+3.04%)
PFE : 25.65 (+2.07%)
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia drug Hympavzi (marstacimab). AstraZeneca’s AZN Tagrisso was recommended...

AZN : 65.63 (+2.13%)
JNJ : 155.17 (-0.21%)
LLY : 748.01 (-0.25%)
NVS : 104.28 (+0.41%)
PFE : 25.65 (+2.07%)
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics

Novartis NVS announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with...

NVS : 104.28 (+0.41%)
GILD : 90.19 (+0.48%)
PFE : 25.65 (+2.07%)
The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair

For Immediate ReleaseChicago, IL – November 21, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and...

DG : 74.93 (+1.37%)
ADBE : 512.15 (+1.53%)
SNAP : 11.42 (+7.43%)
RYAAY : 42.98 (+0.23%)
PFE : 25.65 (+2.07%)
Pfizer Names New Head Of Research And Development

Pharmaceutical giant Pfizer (PFE) has named company veteran Chris Boshoff its chief of research and ...

PFE : 25.65 (+2.07%)
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist

Every company faces challenges. Sometimes, those issues are deeply damaging to a corporation's investment thesis. Other times, though, that's not the case, and the price drop represents a great buying...

MRK : 99.18 (-0.68%)
PFE : 25.65 (+2.07%)
Is Biotech’s Bull Run Over? Examining Election Impacts

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

IBB : 137.96 (+1.37%)
NVAX : 8.47 (+5.35%)
MRNA : 41.11 (+7.48%)
XBI : 96.24 (+2.06%)
PFE : 25.65 (+2.07%)
2 Dividend Stocks That Pay More Than 6% That Retirees Can Safely Buy and Hold for Years

Collecting an above-average dividend payment can sometimes come with risks. High-yielding stocks can be due for cuts to their payouts if a company's underlying financials aren't strong enough to support...

VZ : 43.15 (+1.53%)
PFE : 25.65 (+2.07%)
5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential

U.S. stock markets have been witnessing an impressive rally since the beginning of 2023 barring some minor hurdles. Wall Street’s bull run has got an added boost this year, to the surprise of a large...

DG : 74.93 (+1.37%)
ADBE : 512.15 (+1.53%)
SNAP : 11.42 (+7.43%)
RYAAY : 42.98 (+0.23%)
PFE : 25.65 (+2.07%)
Is It Time to Sell Eli Lilly and Pfizer Stocks?

Arguably, no big pharma stocks have dominated the industry more over the last few years than Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE) .

LLY : 748.01 (-0.25%)
PFE : 25.65 (+2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.55
2nd Resistance Point 26.15
1st Resistance Point 25.90
Last Price 25.65
1st Support Level 25.25
2nd Support Level 24.85
3rd Support Level 24.60

See More

52-Week High 31.54
Fibonacci 61.8% 28.84
Fibonacci 50% 28.01
Fibonacci 38.2% 27.18
Last Price 25.65
52-Week Low 24.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar